MAPT and Alzheimer disease: Biomarkers for amyloid and tau, neurodegeneration, and inflammatory changes in cerebrospinal fluid (CSF) have provided an invaluable foundation of knowledge for understanding the earliest molecular changes that occur in Alzheimer’s disease, as well as a reliable method for establishing the diagnosis of AD [14].